Thyrocare Technologies Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹271 Cr +24.9% YoYSee revenue, profit and what management said. You are viewing Q4 FY25.
TT

Thyrocare Technologies Ltd

Q4 FY25Healthcare Services

Thyrocare Technologies Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management said on revenue, margins and capex.

Revenue
₹187Cr
+21.4% YoY
+12.7% QoQ
Net profit
₹22Cr
+29.4% YoY
+15.8% QoQ
Margin
30%
+8 pp YoY
+5 pp QoQ
Price₹566
Market cap₹9.5K Cr
P/E52.8

The short version

Mid-teens revenue growth expected for FY '26, with cautious optimism due to a high current base and industry growth of 10-11%. Revenue growth guidance for FY '26 is mid-teens percentage, reflecting cautious optimism due to a high base and competitive pressure.

From Thyrocare Technologies Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Mid-teens revenue growth expected for FY '26, with cautious optimism due to a high current base and industry growth of 10-11%.
  • Volume growth anticipated around 14%, aligned closely with revenue growth due to tiered pricing structure, with no material price increases expected.
  • Franchisee network set to expand with plans to add 1,500 to 2,000 new franchise partners annually, supporting growth over next 3-5 years.
  • Partnership business growing strongly, including health tech and corporate/insurance segments, aiding volume and revenue expansion.
  • Continued focus on specialized test menu expansion, including allergy and genomics, poised to drive higher realization and growth.

2 more points from Thyrocare Technologies Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Thyrocare Technologies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • For FY '25, capex was roughly INR 40-50 crores annually.
  • The company has sufficient cash flow to manage capex and acquisitions without stress.
  • No large amount has been set aside for acquisitions in FY '26; expected deployment around INR 15-20 crores focused on weaker geographies (Gujarat, Rajasthan, Northeast).
  • The company pursues a “string of pearls” acquisition strategy—small, focused acquisitions rather than large deals, due to management bandwidth considerations.
  • Capital investment in Nueclear centers is not planned currently, as a new center setup costs around INR 10 crores; focus remains on maintaining and optimizing existing centers.

2 more points from Thyrocare Technologies Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Thyrocare Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Thyrocare Technologies Ltd said on order book & pipeline — free account, 30 seconds.

Thyrocare Technologies Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Thyrocare Technologies Ltd Q4 FY25 results — key figures

Thyrocare Technologies Ltd Q4 FY25 reported results vs Q4 FY24, ₹ crore
₹ CrQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue187154+21.4%166+12.7%
Operating profit (EBITDA)5734+67.6%42+35.7%
Operating margin30%22%+8 pp25%+5 pp
Profit before tax4723+104.3%28+67.9%
Net profit (PAT)2217+29.4%19+15.8%
EPS (₹)1.361.12+21.4%1.20+13.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹271 Cr, net profit ₹15 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • 3B Blackbio (Q4 FY25)

    UK subsidiary (TRUPCR Europe Limited) revenue FY 2024-25: GBP 1,287,580, a 94% increase over FY 2023-24 GBP 664,059. Key concall takeaways from 3B Blackbio DX…

  • Apollo Hospitals (Q4 FY25)

    . Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Shalby (Q4 FY25)

    Implant business is in high-growth mode: 4x growth in Indonesia, 35-40% growth in U.S., and 2.5x growth in India reported last year. Key concall takeaways from…

  • Narayana Hrudaya (Q4 FY25)

    Capex is split between regular maintenance/replacement (~INR 300 crores) and new greenfield/brownfield capacity (~INR 450 crores) with some variability based…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Thyrocare Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Thyrocare Technologies Ltd Q4 FY25 results?

Mid-teens revenue growth expected for FY '26, with cautious optimism due to a high current base and industry growth of 10-11%. Revenue growth guidance for FY '26 is mid-teens percentage, reflecting cautious optimism due to a high base and competitive pressure.

What is Thyrocare Technologies Ltd share price analysis?

Thyrocare Technologies Ltd currently shows a neutral. The stock trades at a P/E of 52.8 with a market cap of ₹9,550 Cr. Investors should review the full earnings analysis for detailed insights.

Is Thyrocare Technologies Ltd planning capital expenditure?

For FY '25, capex was roughly INR 40-50 crores annually.

Keep Thyrocare Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.